rituximab,ibrutinib,Bendamustine
biogen,roche,janssen,abbvie,teva pharmaceuticals,novartis
['rituximab', 'shine']
shine data support bendamustine/rituximab &amp; ibrutinib as a treatment option for #mcl in older pts unsuitable for intensive chemo or transplantation, but added toxicities a concern. #asco22 #ascodailynews #hemonc #lymsym 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.